Literature DB >> 18647598

TNF-alpha upregulates the A2B adenosine receptor gene: The role of NAD(P)H oxidase 4.

Cynthia St Hilaire1, Milka Koupenova, Shannon H Carroll, Barbara D Smith, Katya Ravid.   

Abstract

Proliferation of vascular smooth muscle cells (VSMC), oxidative stress, and elevated inflammatory cytokines are some of the components that contribute to plaque formation in the vasculature. The cytokine tumor necrosis factor-alpha (TNF-alpha) is released during vascular injury, and contributes to lesion formation also by affecting VSMC proliferation. Recently, an A(2B) adenosine receptor (A(2B)AR) knockout mouse illustrated that this receptor is a tissue protector, in that it inhibits VSMC proliferation and attenuates the inflammatory response following injury, including the release of TNF-alpha. Here, we show a regulatory loop by which TNF-alpha upregulates the A(2B)AR in VSMC in vitro and in vivo. The effect of this cytokine is mimicked by its known downstream target, NAD(P)H oxidase 4 (Nox4). Nox4 upregulates the A(2B)AR, and Nox inhibitors dampen the effect of TNF-alpha. Hence, our study is the first to show that signaling associated with Nox4 is also able to upregulate the tissue protecting A(2B)AR.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18647598      PMCID: PMC2583397          DOI: 10.1016/j.bbrc.2008.07.059

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  40 in total

1.  Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage.

Authors:  A Ohta; M Sitkovsky
Journal:  Nature       Date:  2001 Dec 20-27       Impact factor: 49.962

2.  Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms.

Authors:  G Haskó; D G Kuhel; J F Chen; M A Schwarzschild; E A Deitch; J G Mabley; A Marton; C Szabó
Journal:  FASEB J       Date:  2000-10       Impact factor: 5.191

3.  Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo.

Authors:  K Wingler; S Wünsch; R Kreutz; L Rothermund; M Paul; H H Schmidt
Journal:  Free Radic Biol Med       Date:  2001-12-01       Impact factor: 7.376

Review 4.  Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection.

Authors:  J Linden
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

5.  A non-hypoxic, ROS-sensitive pathway mediates TNF-alpha-dependent regulation of HIF-1alpha.

Authors:  J J Haddad; S C Land
Journal:  FEBS Lett       Date:  2001-09-14       Impact factor: 4.124

Review 6.  Inflammation and atherosclerosis.

Authors:  Peter Libby; Paul M Ridker; Attilio Maseri
Journal:  Circulation       Date:  2002-03-05       Impact factor: 29.690

7.  Effect of NADPH oxidase inhibition on E-selectin expression induced by concomitant anoxia/reoxygenation and TNF-alpha.

Authors:  Jérôme R Paysant; Alain Rupin; Tony J Verbeuren
Journal:  Endothelium       Date:  2002

Review 8.  Adenosine production and its interaction with protection of ischemic and reperfusion injury of the myocardium.

Authors:  Toshio Obata
Journal:  Life Sci       Date:  2002-09-20       Impact factor: 5.037

Review 9.  Vascular NAD(P)H oxidases: specific features, expression, and regulation.

Authors:  Bernard Lassègue; Roza E Clempus
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2003-08       Impact factor: 3.619

Review 10.  Inflammation in atherosclerosis.

Authors:  Peter Libby
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

View more
  30 in total

1.  A2b adenosine receptor regulates hyperlipidemia and atherosclerosis.

Authors:  Milka Koupenova; Hillary Johnston-Cox; Alexander Vezeridis; Haralambos Gavras; Dan Yang; Vassilis Zannis; Katya Ravid
Journal:  Circulation       Date:  2011-12-05       Impact factor: 29.690

2.  A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo.

Authors:  Shannon H Carroll; Nathan A Wigner; Nitin Kulkarni; Hillary Johnston-Cox; Louis C Gerstenfeld; Katya Ravid
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

3.  IFN-γ Prevents Adenosine Receptor (A2bR) Upregulation To Sustain the Macrophage Activation Response.

Authors:  Heather B Cohen; Amanda Ward; Kajal Hamidzadeh; Katya Ravid; David M Mosser
Journal:  J Immunol       Date:  2015-09-09       Impact factor: 5.422

Review 4.  Adenosine receptors and caffeine in retinopathy of prematurity.

Authors:  Jiang-Fan Chen; Shuya Zhang; Rong Zhou; Zhenlang Lin; Xiaohong Cai; Jing Lin; Yuqing Huo; Xiaoling Liu
Journal:  Mol Aspects Med       Date:  2017-01-11

Review 5.  A(2B) adenosine receptors in immunity and inflammation.

Authors:  György Haskó; Balázs Csóka; Zoltán H Németh; E Sylvester Vizi; Pál Pacher
Journal:  Trends Immunol       Date:  2009-05-07       Impact factor: 16.687

6.  Activation of the macrophage A2b adenosine receptor regulates tumor necrosis factor-alpha levels following vascular injury.

Authors:  Hongjie Chen; Dan Yang; Shannon H Carroll; Holger K Eltzschig; Katya Ravid
Journal:  Exp Hematol       Date:  2009-05       Impact factor: 3.084

Review 7.  A2 adenosine receptors and vascular pathologies.

Authors:  Hillary A Johnston-Cox; Milka Koupenova; Katya Ravid
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

Review 8.  The Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic Diseases.

Authors:  Anna Eisenstein; Shenia Patterson; Katya Ravid
Journal:  J Cell Physiol       Date:  2015-12       Impact factor: 6.384

9.  Adenosine and blood platelets.

Authors:  Hillary A Johnston-Cox; Katya Ravid
Journal:  Purinergic Signal       Date:  2011-02-08       Impact factor: 3.765

10.  Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant.

Authors:  Rebecca L Williams-Karnesky; Mary P Stenzel-Poore
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.